0001127703false00011277032024-11-072024-11-07
| | | | | |
UNITED STATES |
SECURITIES AND EXCHANGE COMMISSION |
Washington, D.C. 20549 |
| |
FORM | 8-K |
CURRENT REPORT |
| |
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 |
|
Date of Report (Date of earliest event reported): November 7, 2024 |
|
ProAssurance Corporation |
(Exact name of registrant as specified in its charter) |
| | | | | | | | |
Delaware | 001-16533 | 63-1261433 |
(State of Incorporation) | (Commission File No.) | (IRS Employer I.D. No.) |
| | | | | | | | | | | |
100 Brookwood Place, | Birmingham, | AL | 35209 |
(Address of Principal Executive Office ) | (Zip code) |
| | | | | | | | |
Registrant’s telephone number, including area code: | (205) | 877-4400 |
| | | | | |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Securities Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-(c) under the Exchange Act (17CFR 240.13e-(c)) |
| | | | | | | | |
Securities registered pursuant to Section 12(b) of the Act: |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, par value $0.01 per share | PRA | New York Stock Exchange |
| | | | | |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ |
ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION
On November 7, 2024 we issued a news release reporting the results of our operations for the quarter and nine months ended September 30, 2024. The text of the release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
ITEM 7.01 REGULATION FD DISCLOSURES
We are furnishing investor presentation materials to be used starting November 7, 2024 as Exhibit 99.2. The presentation is available under Presentations under the News & Presentation Materials tab of the Investor Relations section of our website (http://investor.proassurance.com).
We also have updated our online disclosure of our entire investment portfolio to provide details of our holdings through September 30, 2024. The disclosure is available under Quarterly Investment Supplements under the Financial Information section of the Investor Relations section of our website.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
The information we are furnishing under Items 7.01 and 9.01 of this Current Report on Form 8K, including Exhibits 99.1and 99.2, are not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) as amended, or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 7, 2024
| | |
PROASSURANCE CORPORATION |
by: /s/ Jeffrey P. Lisenby |
----------------------------------------------------- |
Jeffrey P. Lisenby General Counsel |
| | | | | |
NEWS RELEASE For More Information: Heather J. Wietzel • SVP, Investor Relations 800-282-6242 • 205-776-3028 • InvestorRelations@ProAssurance.com | |
ProAssurance Reports Results for Third Quarter 2024
BIRMINGHAM, AL – November 7, 2024 – ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability and a core small-cap value equity in the financials sector, today reported net income of $16.4 million, or $0.32 per diluted share, and operating income(1) of $17.3 million, or $0.34 per diluted share, for the three months ended September 30, 2024.
Third Quarter 2024(2)
•Specialty P&C segment combined ratio of 99.5% demonstrates progress resulting from management’s ongoing actions focused on achieving sustained profitability
•Net investment income increased 14% as we take advantage of the current interest rate environment as the portfolio matures
•Earnings benefited from solid returns from limited partnership investments (reported as equity in earnings of unconsolidated subsidiaries)
•Book value per share was $24.07 at September 30, 2024, up $2.25 from $21.82 at year-end 2023 due to net income of $37 million for the first nine months of 2024 as well as after-tax unrealized holding gains of $77 million from our fixed maturity portfolio; non-GAAP adjusted book value per share(1) rose to $26.52 from $25.83
(1) Represents a Non-GAAP financial measure. See a reconciliation to its GAAP counterpart under the heading “Non-GAAP Financial Measures” that follows.
(2) Comparisons are to the third quarter of 2023 unless otherwise noted.
Management Commentary & Results of Operations
“Operating earnings for the third quarter reflected our growing confidence in the impact of the actions we have taken over the past several years, with the Specialty P&C segment delivering a combined ratio of 99.5%, including net favorable prior accident year reserve development of 10.5 points,” said Ned Rand, President and Chief Executive Officer of ProAssurance. He added, “This segment, which is largely made up of our Medical Professional Liability line of business, represents more than 75% of total earned premium. We believe we are ahead of many in this space in achieving rate levels that put us on track to outpace severity trends that remain challenging.
“Specialty P&C renewal premium increases of 13% this quarter are part of the cumulative +65% premium change we have accomplished since 2018,” Rand added. “We continue to forgo renewal and new business opportunities that we believe do not meet our expectation of rate adequacy in the current loss environment, although retention for the Specialty P&C segment remained a solid 84%. In this loss environment, we will continue to focus on our targeted healthcare market segments with disciplined claims management and underwriting.
Rand noted, “Our long history in the insurance markets we serve makes us confident that these cyclical lines will respond to our focused efforts. However, current market conditions continue to be a headwind that make it prudent to shrink in some markets to help us reach our target for long-term sustained profitability across all business segments, before turning our focus to growth.”
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | |
CONSOLIDATED INCOME STATEMENT HIGHLIGHTS |
Selected consolidated financial data for each period is summarized in the table below. |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
($ in thousands, except per share data) | 2024 | | 2023 | | Change | | 2024 | | 2023 | | Change |
Revenues | | | | | | | | | | | |
Gross premiums written(1) | $ | 307,940 | | | $ | 319,762 | | | (3.7 | %) | | $ | 843,202 | | | $ | 873,484 | | | (3.5 | %) |
Net premiums written | $ | 279,546 | | | $ | 292,023 | | | (4.3 | %) | | $ | 765,130 | | | $ | 790,978 | | | (3.3 | %) |
Net premiums earned | $ | 243,160 | | | $ | 242,420 | | | 0.3 | % | | $ | 727,176 | | | $ | 730,068 | | | (0.4 | %) |
Net investment income | 37,272 | | | 32,754 | | | 13.8 | % | | 107,727 | | | 94,714 | | | 13.7 | % |
Equity in earnings (loss) of unconsolidated subsidiaries | 4,767 | | | (61) | | | 7,914.8 | % | | 16,383 | | | 5,450 | | | 200.6 | % |
Net investment gains (losses)(2) | 2,252 | | | (2,702) | | | 183.3 | % | | 5,146 | | | 3,156 | | | 63.1 | % |
Other income (expense)(1) | (2,198) | | | 3,336 | | | (165.9 | %) | | 3,872 | | | 6,864 | | | (43.6 | %) |
Total revenues(1) | 285,253 | | | 275,747 | | | 3.4 | % | | 860,304 | | | 840,252 | | | 2.4 | % |
Expenses | | | | | | | | | | | |
Net losses and loss adjustment expenses | 176,331 | | | 208,891 | | | (15.6 | %) | | 557,025 | | | 605,245 | | | (8.0 | %) |
Underwriting, policy acquisition and operating expenses(1) | 80,389 | | | 74,014 | | | 8.6 | % | | 238,408 | | | 218,779 | | | 9.0 | % |
SPC U.S. federal income tax expense (benefit) | 377 | | | (175) | | | 315.4 | % | | 1,043 | | | 1,351 | | | (22.8 | %) |
SPC dividend expense (income) | 1,360 | | | (2,518) | | | 154.0 | % | | 2,479 | | | 3,171 | | | (21.8 | %) |
Interest expense | 5,698 | | | 5,514 | | | 3.3 | % | | 17,004 | | | 16,478 | | | 3.2 | % |
Goodwill impairment | — | | | 44,110 | | | nm | | — | | | 44,110 | | | nm |
Total expenses(1) | 264,155 | | | 329,836 | | | (19.9 | %) | | 815,959 | | | 889,134 | | | (8.2 | %) |
| | | | | | | | | | | |
Income (loss) before income taxes | 21,098 | | | (54,089) | | | 139.0 | % | | 44,345 | | | (48,882) | | | 190.7 | % |
Income tax expense (benefit) | 4,657 | | | (4,655) | | | 200.0 | % | | 7,770 | | | (3,901) | | | 299.2 | % |
Net income (loss) | $ | 16,441 | | | $ | (49,434) | | | 133.3 | % | | $ | 36,575 | | | $ | (44,981) | | | 181.3 | % |
Non-GAAP operating income (loss) | $ | 17,288 | | | $ | (5,077) | | | 440.5 | % | | $ | 33,003 | | | $ | (4,783) | | | 790.0 | % |
Weighted average number of common shares outstanding | | | | | | | | | | | |
Basic | 51,156 | | | 51,837 | | | | | 51,077 | | | 53,205 | | | |
Diluted | 51,277 | | | 52,006 | | | | | 51,217 | | | 53,339 | | | |
Earnings (loss) per share | | | | | | | | | | | |
Net income (loss) per diluted share | $ | 0.32 | | | $ | (0.95) | | | $ | 1.27 | | | $ | 0.71 | | | $ | (0.85) | | | $ | 1.56 | |
Non-GAAP operating income (loss) per diluted share | $ | 0.34 | | | $ | (0.10) | | | $ | 0.44 | | | $ | 0.64 | | | $ | (0.09) | | | $ | 0.73 | |
|
(1) Consolidated totals include inter-segment eliminations. The eliminations affect individual line items only and have no effect on net income (loss). See Note 13 of the Notes to Condensed Consolidated Financial Statements in our September 30, 2024 report on Form 10-Q for amounts by line item.
(2) This line item typically includes both realized and unrealized investment gains and losses, investment impairments losses, and the change in the fair value of the contingent consideration in relation to the NORCAL acquisition. Detailed information regarding the components of net investment gains (losses) are included in Note 3 of the Notes to Condensed Consolidated Financial Statements in our September 30, 2024 report on Form 10-Q.
The abbreviation “nm” indicates that the information or the percentage change is not meaningful.
| | | | | | | | | | | |
BALANCE SHEET HIGHLIGHTS |
($ in thousands, except per share data) | September 30, 2024 | | December 31, 2023 |
Total investments | $ | 4,461,116 | | | $ | 4,349,781 | |
Total assets | $ | 5,732,372 | | | $ | 5,631,925 | |
Total liabilities | $ | 4,501,146 | | | $ | 4,519,945 | |
Common shares (par value $0.01) | $ | 638 | | | $ | 636 | |
Retained earnings | $ | 1,418,556 | | | $ | 1,381,981 | |
Treasury shares | $ | (469,702) | | | $ | (469,702) | |
Shareholders’ equity | $ | 1,231,226 | | | $ | 1,111,980 | |
Book value per share | $ | 24.07 | | | $ | 21.82 | |
Non-GAAP adjusted book value per share(1) | $ | 26.52 | | | $ | 25.83 | |
(1) Adjusted book value per share is a Non-GAAP financial measure. See a reconciliation of book value per share to Non-GAAP adjusted book value per share under the heading “Non-GAAP Financial Measures” that follows. |
| | | | | | | | | | | | | | | | | | | | | | | |
CONSOLIDATED KEY RATIOS |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
| 2024 | | 2023 | | 2024 | | 2023 |
Current accident year net loss ratio | 81.5 | % | | 83.0 | % | | 80.5 | % | | 81.8 | % |
Effect of prior accident years’ reserve development | (9.0 | %) | | 3.2 | % | | (3.9 | %) | | 1.1 | % |
Net loss ratio | 72.5 | % | | 86.2 | % | | 76.6 | % | | 82.9 | % |
Underwriting expense ratio | 33.1 | % | | 30.5 | % | | 32.8 | % | | 30.0 | % |
Combined ratio | 105.6 | % | | 116.7 | % | | 109.4 | % | | 112.9 | % |
Operating ratio | 90.3 | % | | 103.2 | % | | 94.6 | % | | 99.9 | % |
Return on equity(1) | 5.6 | % | | (18.6 | %) | | 4.2 | % | | (5.7 | %) |
Non-GAAP operating return on equity(1)(2) | 5.9 | % | | (1.9 | %) | | 3.8 | % | | (0.6 | %) |
| | | | | | | |
| | | | | | | |
(1) Annualized. Refer to our September 30, 2024 report on Form 10-Q under the heading “Non-GAAP Operating ROE” in the Executive Summary of Operations section for details on our calculation. |
(2) See a reconciliation of ROE to Non-GAAP operating ROE under the heading “Non-GAAP Financial Measures” that follows. |
|
|
SPECIALTY P&C SEGMENT RESULTS
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
($ in thousands) | 2024 | | 2023 | | % Change | | 2024 | | 2023 | | % Change |
Gross premiums written | $ | 244,007 | | | $ | 256,125 | | | (4.7 | %) | | $ | 645,902 | | | $ | 673,660 | | | (4.1 | %) |
Net premiums written | $ | 221,490 | | | $ | 241,888 | | | (8.4 | %) | | $ | 589,209 | | | $ | 607,945 | | | (3.1 | %) |
Net premiums earned | $ | 188,704 | | | $ | 195,772 | | | (3.6 | %) | | $ | 562,137 | | | $ | 562,206 | | | — | % |
Other income (expense) | 982 | | | 1,089 | | | (9.8 | %) | | 3,359 | | | 3,106 | | | 8.1 | % |
Total revenues | 189,686 | | | 196,861 | | | (3.6 | %) | | 565,496 | | | 565,312 | | | — | % |
Net losses and loss adjustment expenses | (136,337) | | | (162,677) | | | (16.2 | %) | | (434,564) | | | (476,187) | | | (8.7 | %) |
Underwriting, policy acquisition and operating expenses | (51,492) | | | (49,395) | | | 4.2 | % | | (153,415) | | | (140,949) | | | 8.8 | % |
Total expenses | (187,829) | | | (212,072) | | | (11.4 | %) | | (587,979) | | | (617,136) | | | (4.7 | %) |
Segment results | $ | 1,857 | | | $ | (15,211) | | | 112.2 | % | | $ | (22,483) | | | $ | (51,824) | | | 56.6 | % |
| | | | | | | | | | | | | | | | | | | | | | | |
SPECIALTY P&C SEGMENT KEY RATIOS |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
| 2024 | | 2023 | | 2024 | | 2023 |
Current accident year net loss ratio | 82.7 | % | | 83.4 | % | | 82.1 | % | | 84.4 | % |
Effect of prior accident years’ reserve development | (10.5 | %) | | (0.3 | %) | | (4.8 | %) | | 0.3 | % |
Net loss ratio | 72.2 | % | | 83.1 | % | | 77.3 | % | | 84.7 | % |
Underwriting expense ratio | 27.3 | % | | 25.2 | % | | 27.3 | % | | 25.1 | % |
Combined ratio | 99.5 | % | | 108.3 | % | | 104.6 | % | | 109.8 | % |
ProAssurance is a leader in the competitive Medical Professional Liability market, which made up almost 90% of Specialty P&C segment gross written premiums for the year ended December 31, 2023.
For the quarter, the segment’s combined ratio improved 8.8 percentage points compared to last year’s third quarter, primarily due to a lower net loss ratio that reflected our continued focus on price adequacy and cautious underwriting as well as our ability to target segments within healthcare where there are opportunities to write business that we believe will meet our profitability objectives.
•Premiums: Renewal pricing remained strong at 13% for the segment. Retention was a solid 84% while new business of $8.3 million remained well below last year as we focus on risk selection and pricing levels that support progress toward our profitability targets.
•Net loss ratio: Current accident year net loss ratio improved 0.7 percentage points over last year, primarily due to our underwriting actions and pricing we have achieved over the course of the past 12 months. Net favorable prior accident year reserve development was $19.7 million, improving the net loss ratio by 10.5 percentage points, largely reflecting favorable claims-closing trends in the Medical Professional Liability business, primarily for accident years 2018 and prior in our legacy ProAssurance business as well as accident year 2021 from our NORCAL book.
•Underwriting expense ratio: Year-over-year increase of just over 2 percentage points, largely due to higher compensation-related costs.
WORKERS’ COMPENSATION INSURANCE SEGMENT RESULTS
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
($ in thousands) | 2024 | | 2023 | | % Change | | 2024 | | 2023 | | % Change |
Gross premiums written | $ | 63,933 | | | $ | 63,637 | | | 0.5 | % | | $ | 197,292 | | | $ | 199,824 | | | (1.3 | %) |
Net premiums written | $ | 46,318 | | | $ | 44,386 | | | 4.4 | % | | $ | 136,664 | | | $ | 134,280 | | | 1.8 | % |
| | | | | | | | | | | |
Net premiums earned | $ | 41,829 | | | $ | 39,885 | | | 4.9 | % | | $ | 124,692 | | | $ | 121,706 | | | 2.5 | % |
Other income (expense) | 537 | | | 333 | | | 61.3 | % | | 1,483 | | | 1,565 | | | (5.2 | %) |
Total revenues | 42,366 | | | 40,218 | | | 5.3 | % | | 126,175 | | | 123,271 | | | 2.4 | % |
| | | | | | | | | | | |
Net losses and loss adjustment expenses | (32,193) | | | (41,208) | | | (21.9 | %) | | (95,980) | | | (101,813) | | | (5.7 | %) |
Underwriting, policy acquisition and operating expenses | (14,383) | | | (13,542) | | | 6.2 | % | | (44,008) | | | (40,923) | | | 7.5 | % |
Total expenses | (46,576) | | | (54,750) | | | (14.9 | %) | | (139,988) | | | (142,736) | | | (1.9 | %) |
Segment results | $ | (4,210) | | | $ | (14,532) | | | 71.0 | % | | $ | (13,813) | | | $ | (19,465) | | | 29.0 | % |
| | | | | | | | | | | | | | | | | | | | | | | |
WORKERS’ COMPENSATION INSURANCE SEGMENT KEY RATIOS |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
| 2024 | | 2023 | | 2024 | | 2023 |
Current accident year net loss ratio | 77.0 | % | | 83.1 | % | | 77.0 | % | | 76.0 | % |
Effect of prior accident years’ reserve development | — | % | | 20.2 | % | | — | % | | 7.7 | % |
Net loss ratio | 77.0 | % | | 103.3 | % | | 77.0 | % | | 83.7 | % |
Underwriting expense ratio | 34.4 | % | | 34.0 | % | | 35.3 | % | | 33.6 | % |
Combined ratio | 111.4 | % | | 137.3 | % | | 112.3 | % | | 117.3 | % |
ProAssurance is a specialty regional underwriter of workers’ compensation products and services. The third quarter 2024 combined ratio for the Workers’ Compensation Insurance segment improved 10 percentage points compared to the full-year 2023 segment combined ratio due to a lower calendar year net loss ratio.
•Premiums: Higher audit premiums were the primary reason for the increase in net written premiums. We continue to carefully manage our underwriting appetite due to market conditions. Retention was 82% although we saw improved renewal pricing. New business was $3.3 million, down from $5.4 million in last year’s third quarter.
•Net loss ratio: Current accident year net loss ratio of 77.0% improved 4.3 points from the 81.3% for full-year 2023. We also continue to observe and reflect the higher medical loss cost trends that we initially saw in the second half of 2023, although they have begun to moderate this year. There was no change in prior accident year reserves for this segment in this year’s third quarter compared to substantial reserve strengthening in last year’s third quarter due to the higher than expected loss trends observed at that time.
•Underwriting expense ratio: Year-over-year increase of 0.4 percentage point was largely due to higher compensation-related costs.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | |
SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT RESULTS |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
($ in thousands) | 2024 | | 2023 | | % Change | | 2024 | | 2023 | | % Change |
Gross premiums written | $ | 13,650 | | | $ | 7,930 | | | 72.1 | % | | $ | 45,467 | | | $ | 55,924 | | | (18.7 | %) |
Net premiums written | $ | 11,738 | | | $ | 5,749 | | | 104.2 | % | | $ | 39,257 | | | $ | 48,753 | | | (19.5 | %) |
| | | | | | | | | | | |
Net premiums earned | $ | 12,627 | | | $ | 6,763 | | | 86.7 | % | | $ | 40,347 | | | $ | 46,156 | | | (12.6 | %) |
Net investment income | 1,009 | | | 601 | | | 67.9 | % | | 2,687 | | | 1,625 | | | 65.4 | % |
Net investment gains (losses) | 599 | | | (525) | | | 214.1 | % | | 2,327 | | | 1,830 | | | 27.2 | % |
Other income (expense) | 1 | | | 2 | | (50.0 | %) | | 1 | | | 3 | | | (66.7 | %) |
Net losses and loss adjustment expenses | (7,801) | | | (5,006) | | | 55.8 | % | | (26,481) | | | (27,245) | | | (2.8 | %) |
Underwriting, policy acquisition and operating expenses | (4,143) | | | (3,668) | | | 12.9 | % | | (14,105) | | | (15,241) | | | (7.5 | %) |
SPC U.S. federal income tax (expense) benefit(1) | (377) | | | 175 | | | 315.4 | % | | (1,043) | | | (1,351) | | | (22.8 | %) |
SPC net results | 1,915 | | | (1,658) | | | 215.5 | % | | 3,733 | | | 5,777 | | | (35.4 | %) |
SPC dividend (expense) income (2) | (1,360) | | | 2,518 | | | 154.0 | % | | (2,479) | | | (3,171) | | | (21.8 | %) |
Segment results (3) | $ | 555 | | | $ | 860 | | | (35.5 | %) | | $ | 1,254 | | | $ | 2,606 | | | (51.9 | %) |
(1) Represents the provision for U.S. federal income taxes for SPCs at Inova Re, which have elected to be taxed as a U.S. corporation under Section 953(d) of the Internal Revenue Code. U.S. federal income taxes are included in the total SPC net results and are paid by the individual SPCs. |
(2) Represents the net (profit) loss attributable to external cell participants. |
(3) Represents our share of the net profit (loss) and OCI of the SPCs in which we participate. |
| | | | | | | | | | | | | | | | | | | | | | | |
SEGREGATED PORTFOLIO CELL REINSURANCE SEGMENT KEY RATIOS |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
| 2024 | | 2023 | | 2024 | | 2023 |
Current accident year net loss ratio | 77.9 | % | | 70.5 | % | | 69.5 | % | | 64.7 | % |
Effect of prior accident years’ reserve development | (16.1 | %) | | 3.5 | % | | (3.9 | %) | | (5.7 | %) |
Net loss ratio | 61.8 | % | | 74.0 | % | | 65.6 | % | | 59.0 | % |
Underwriting expense ratio | 32.8 | % | | 54.2 | % | | 35.0 | % | | 33.0 | % |
Combined ratio | 94.6 | % | | 128.2 | % | | 100.6 | % | | 92.0 | % |
|
Segregated Portfolio Cell Reinsurance segment results include underwriting profit or loss plus investment results, net of U.S. federal income taxes of segregated portfolio cells in which we participate. For the third quarter, the segment reported a profit of $0.6 million compared to $0.9 million in last year’s third quarter. Results for the current quarter largely reflected elevated reported loss activity offset by favorable prior accident year development.
CORPORATE SEGMENT
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
($ in thousands) | 2024 | | 2023 | | % Change | | 2024 | | 2023 | | % Change |
Net investment income | $ | 36,263 | | | $ | 32,153 | | | 12.8 | % | | $ | 105,040 | | | $ | 93,089 | | | 12.8 | % |
Equity in earnings (loss) of unconsolidated subsidiaries: | | | | | | | | | | | |
All other investments, primarily investment fund LPs/LLCs | 5,218 | | | 368 | | | 1317.9 | % | | 16,546 | | | 7,744 | | | 113.7 | % |
Tax credit partnerships | (451) | | | (429) | | | 5.1 | % | | (163) | | | (2,294) | | | (92.9 | %) |
Total equity in earnings (loss) of unconsolidated subsidiaries: | 4,767 | | | (61) | | | 7914.8 | % | | 16,383 | | | 5,450 | | | 200.6 | % |
Net investment gains (losses) | 1,653 | | | (3,677) | | | 145.0 | % | | (3,921) | | | (3,174) | | | (23.5 | %) |
Other income (expense) | (2,747) | | | 2,847 | | | (196.5 | %) | | 2,281 | | | 5,347 | | | (57.3 | %) |
Operating expenses | (11,342) | | | (8,344) | | | 35.9 | % | | (29,812) | | | (24,823) | | | 20.1 | % |
Interest expense | (5,698) | | | (5,514) | | | 3.3 | % | | (17,004) | | | (16,478) | | | 3.2 | % |
Income tax (expense) benefit | (4,657) | | | 4,655 | | | 200.0 | % | | (7,837) | | | 3,901 | | | 300.9 | % |
Segment results | $ | 18,239 | | | $ | 22,059 | | | (17.3 | %) | | $ | 65,130 | | | $ | 63,312 | | | 2.9 | % |
| | | | | | | | | | | |
Consolidated effective tax rate | 22.1% | | 8.6% | | | | 17.5% | | 8.0% | | |
The Corporate segment, which includes investment results for our Specialty P&C and Workers’ Compensation Insurance segments, continues to contribute meaningfully to operating results and reported earnings of $18.2 million for the quarter.
•Net investment income: The current interest rate environment continues to benefit our net investment income, which increased again in the quarter, driven by higher average book yields on our fixed maturity investments. During the quarter, we reinvested at an average new money rate of approximately 5.2% for the consolidated portfolio, exceeding the rate on maturing assets and our consolidated average book yield of 3.6%.
•Equity in earnings of unconsolidated subsidiaries: Our investments in limited partnerships, typically reported to us on a one-quarter lag, continued to produce strong returns in the quarter.
•Other income (expense): Reflected changes in exchange rates for foreign currency denominated loss reserves, which are not included in our operating results.
•Operating expenses: The year-over-year increase in expenses in the quarter was largely due to higher compensation-related costs.
•Net investment gains: While not included in our operating results, net investment gains in the quarter were driven by unrealized holding gains from changes in the fair value of our equity investments.
NON-GAAP FINANCIAL MEASURES
Non-GAAP Operating Income (Loss)
Non-GAAP operating income (loss) is a financial measure that is widely used to evaluate performance within the insurance sector. In calculating Non-GAAP operating income (loss), we have excluded the effects of the items listed in the following table that do not reflect normal results. We believe Non-GAAP operating income (loss) presents a useful view of the performance of our insurance operations; however, it should be considered in conjunction with net income (loss) computed in accordance with GAAP. The following table reconciles net income (loss) to Non-GAAP operating income (loss):
| | | | | | | | | | | | | | | | | | | | | | | |
RECONCILIATION OF NET INCOME (LOSS) TO NON-GAAP OPERATING INCOME (LOSS) |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
($ in thousands, except per share data) | 2024 | | 2023 | | 2024 | | 2023 |
Net income (loss) | $ | 16,441 | | | $ | (49,434) | | | $ | 36,575 | | | $ | (44,981) | |
Items excluded in the calculation of Non-GAAP operating income (loss): | | | | | | | |
Net investment (gains) losses (1) | (2,252) | | | 2,702 | | | (5,146) | | | (3,156) | |
Net investment gains (losses) attributable to SPCs in which no profit/loss is retained (2) | 416 | | | (431) | | | 1,743 | | | 1,421 | |
Transaction-related costs (3) | — | | | — | | | 320 | | | — | |
Goodwill impairment | — | | | 44,110 | | | — | | | 44,110 | |
Foreign currency exchange rate (gains) losses (4) | 3,849 | | | (1,705) | | | 1,409 | | | (491) | |
Non-operating income (5) | — | | | — | | | — | | | (1,462) | |
Guaranty fund assessments (recoupments) | (899) | | | 103 | | | (871) | | | 29 | |
| | | | | | | |
Pre-tax effect of exclusions | 1,114 | | | 44,779 | | | (2,545) | | | 40,451 | |
Tax effect, at 21% (6) | (267) | | | (422) | | | (1,027) | | | (253) | |
After-tax effect of exclusions | 847 | | | 44,357 | | | (3,572) | | | 40,198 | |
Non-GAAP operating income (loss) | $ | 17,288 | | | $ | (5,077) | | | $ | 33,003 | | | $ | (4,783) | |
Per diluted common share: | | | | | | | |
Net income (loss) | $ | 0.32 | | | $ | (0.95) | | | $ | 0.71 | | | $ | (0.85) | |
Effect of exclusions | 0.02 | | | 0.85 | | | (0.07) | | | 0.76 | |
Non-GAAP operating income (loss) per diluted common share | $ | 0.34 | | | $ | (0.10) | | | $ | 0.64 | | | $ | (0.09) | |
|
(1) Net investment gains (losses) recognized in earnings are primarily driven by changes in the value of investments that are marked to fair value each period, the nature and timing of which are unrelated to our normal operating results. Net investment gains (losses) for the nine months ended September 30, 2024 include the $6.5 million decrease to the contingent consideration liability during the second quarter of 2024. Net investment gains (losses) during the three and nine months ended September 30, 2023, include gains of $1.5 million and $4.5 million, respectively, related to the remeasurement of the contingent consideration liability to fair value. See further discussion around the contingent consideration in Notes 2 and 7 of the Notes to Condensed Consolidated Financial Statements of our September 30, 2024 report on From 10-Q.
(2) Net investment gains (losses) on investments related to SPCs are recognized in our Segregated Portfolio Cell Reinsurance segment. SPC results, including any net investment gain or loss, that are attributable to external cell participants are reflected in the SPC dividend expense (income). To be consistent with our exclusion of net investment gains (losses) recognized in earnings, we are excluding the portion of net investment gains (losses) that is included in the SPC dividend expense (income) which is attributable to the external cell participants.
(3) Transaction-related costs are attributable to actuarial consulting fees paid during the second quarter of 2024 in relation to the final determination of contingent consideration associated with the NORCAL acquisition. See additional discussion under the heading "Contingent Consideration" in the Financing Activities and Related Cash Flows section in our September 30, 2024 report on From 10-Q. We are excluding these costs as they do not reflect normal operating results and are unique and non-recurring in nature.
(4) Foreign currency exchange rate gains (losses) relate to the impact of foreign exchange rate movements on foreign currency denominated loss reserves predominately associated with premium assumed from an international medical professional liability insured in our Specialty P&C segment. Our participation in this program has grown in recent years which has led to greater volatility in our results of operations even with nominal movements in exchange rates given the size of the reserve. We mitigate foreign exchange rate exposure on our Condensed Consolidated Balance Sheet by generally matching the currency and duration of associated investments to the corresponding loss reserves as well as utilizing foreign currency forward contracts. When we invest in foreign currency denominated available-for-sale fixed maturities, in accordance with GAAP, the change in market value due to changes in foreign currency exchange rates is reflected as a part of OCI. Conversely, the impact of changes in foreign currency exchange rates on loss reserves is reflected through net income (loss) as a component of other income (expense). Therefore, we believe foreign currency exchange rate gains (losses) in our Condensed Consolidated Statements of Income and Comprehensive Income in isolation are not indicative of our operating performance.
(5) Proceeds associated with the sale of a portion of our ownership interest in the underwriting and operations entity associated with Syndicate 1729 to an unrelated third party recognized in other income in our Corporate segment. We are excluding these costs as they do not reflect normal operating results and are unique and non-recurring in nature.
(6) The 21% rate is the annual expected statutory tax rate associated with the taxable or tax deductible items listed above. We utilized the estimated annual effective tax rate method for the nine months ended September 30, 2024, while we used the discrete effective tax method for the nine months ended 2023. See further discussion on this method in the Critical Accounting Estimates section under the heading "Estimation of Taxes" and in Note 4 of the Notes to Condensed Consolidated Financial Statements in our September 30, 2024 report on Form 10-Q. For the 2024 periods, our effective tax rate was applied to these items in calculating net income (loss), excluding net investment gains (losses) and related adjustments which were treated as discrete items and were tax effected at the annual expected statutory tax rate (21%) in the period they were included in our consolidated tax provision and net income (loss). For the 2023 periods, our statutory tax rate was applied to these items in calculating net income (loss), excluding the 2023 goodwill impairment loss which is not tax deductible. Changes related to the fair value of the contingent consideration were non-taxable and therefore had no associated income tax impact. The taxes associated with the net investment gains (losses) related to SPCs in our Segregated Portfolio Cell Reinsurance segment are paid by the individual SPCs and are not included in our consolidated tax provision or net income (loss); therefore, both the net investment gains (losses) from our Segregated Portfolio Cell Reinsurance segment and the adjustment to exclude the portion of net investment gains (losses) included in the SPC dividend expense (income) in the table above are not tax effected.
Non-GAAP Operating ROE
The following table is a reconciliation of ROE to Non-GAAP operating ROE for the three and nine months ended September 30, 2024 and 2023:
| | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended September 30 | | Nine Months Ended September 30 |
| 2024 | | 2023 | | 2024 | | 2023 | |
ROE(1) | 5.6 | % | | (18.6 | %) | | 4.2 | % | | (5.7 | %) | |
Effect of items excluded in the calculation of Non-GAAP operating ROE | 0.3 | % | | 16.7 | % | | (0.4 | %) | | 5.1 | % | |
| | | | | | | | |
Non-GAAP operating ROE | 5.9 | % | | (1.9 | %) | | 3.8 | % | | (0.6 | %) | |
(1) Annualized. Refer to our September 30, 2024 report on Form 10-Q under the heading “Non-GAAP Operating ROE” in the Executive Summary of Operations section for details on our calculation. |
|
Non-GAAP Adjusted Book Value per Share
The following table is a reconciliation of our book value per share to Non-GAAP adjusted book value per share at September 30, 2024 and December 31, 2023:
| | | | | |
| Book Value Per Share |
Book Value Per Share at December 31, 2023 | $ | 21.82 | |
Less: AOCI Per Share(1) | (4.01) | |
Non-GAAP Adjusted Book Value Per Share at December 31, 2023 | 25.83 |
Increase (decrease) to Non-GAAP Adjusted Book Value Per Share during the nine months ended September 30, 2024 attributable to: | |
| |
| |
| |
| |
Net income (loss) | 0.71 | |
| |
Other(2) | (0.02) | |
Non-GAAP Adjusted Book Value Per Share at September 30, 2024 | 26.52 | |
Add: AOCI Per Share(1) | (2.45) | |
Book Value Per Share at September 30, 2024 | $ | 24.07 | |
(1) Primarily the impact of accumulated unrealized investment gains (losses) on our available-for-sale fixed maturity investments. See Note 10 of the Notes to Condensed Consolidated Financial Statements in our September 30, 2024 report on Form 10-Q for additional information. |
|
|
|
(2) Includes the impact of share-based compensation. |
Conference Call Information
ProAssurance management will discuss third quarter 2024 results during a conference call at 10:00 a.m. ET on Friday, November 8, 2024. Preregistration for the call is available here and the dial-in numbers are (833) 470-1428 (toll free) or (404) 975-4839, access code 070621.
Investors are encouraged to listen to the live audio webcast of the call that can also be accessed via the Events page of the Company’s website. A replay of the call will be available at the same location later in the day on November 8.
About ProAssurance
ProAssurance Corporation is an industry-leading specialty insurer with extensive expertise in medical professional liability and products liability for medical technology and life sciences. The company also is a provider of workers’ compensation insurance in the eastern U.S. ProAssurance Group is rated “A” (Excellent) by AM Best.
For the latest on ProAssurance and its industry-leading suite of products and services, cutting-edge risk management and practice enhancement programs, visit our website at ProAssuranceGroup.com with investor content available at Investor.ProAssurance.com. Our YouTube channel regularly presents insightful videos that communicate effective practice management, patient safety and risk management strategies.
Caution Regarding Forward-Looking Statements
Any statements in this news release that are not historical facts or explicitly stated as an opinion are specifically identified as forward-looking statements. These statements are based upon our estimates and anticipation of future events and are subject to significant risks, assumptions and uncertainties that could cause actual results to differ materially from the expected results described in the forward-looking statements. Forward-looking statements are identified by words such as, but not limited to, “anticipate,” “believe,” “estimate,” “expect,” “hope,” “hopeful,” “intend,” “likely,” “may,” “optimistic,” “possible,” “potential,” “preliminary,” “project,” “should,” “will,” and other analogous expressions.
Although it is not possible to identify all of these risks and factors, they include, among others, the following: inadequate loss reserves to cover the Company's actual losses; inherent uncertainty of models resulting in actual losses that are materially different than the Company's estimates; adverse economic factors; a decline in the Company's financial strength rating; loss of one or more key executives; loss of a group of agents or brokers that generate significant portions of the Company's business; failure of any of the loss limitations or exclusions the Company employs, or change in other claims or coverage issues; adverse performance of the Company's investment portfolio; adverse market conditions that affect its excess and surplus lines insurance operations; and other risks described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this release and the Company does not undertake and specifically declines any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.
#####
Investor Update Accurate as of November 7, 2024 Third Quarter 2024 Investor Update Learn more: • News release issued November 7 • 10-Q filed November 7 • Quarterly investor call November 8
©2024 ProAssurance • All rights reserved. 2 Our Shared Vision We will be the best in the world at understanding and providing solutions for the risks our customers encounter as healers, innovators, employers, and professionals. Through an integrated family of specialty companies, products, and services, we will be a trusted partner enabling those we serve to focus on their vital work. As the Employer of Choice, we embrace every day as a singular opportunity to reach for extraordinary outcomes, build and deepen superior relationships, advance diversity, equity, and inclusion, and accomplish our mission with infectious enthusiasm and unbending integrity. Our Core Values • Unbending Integrity • Leadership That Works • Superior Relationships • Infectious Enthusiasm The ProAssurance Mission: We protect others. Over 1,000 Team Members Serving Insureds in 50 states and Washington, D.C. Net Earned Premium for Full-year 2023 $977M Total Assets at Year-end 2023 $5.6B Shareholder's Equity at Year-end 2023 $1.1B A.M. Best Rating "A" (Excellent)
©2024 ProAssurance • All rights reserved. 3 ProAssurance Corporation (SNL P&C Group) 2023 Reported: MPL Direct Premiums Written > $45 million $25-45 million $15-25 million $5-$15 million < $5 million Fourth largest Medical Professional Liability (MPL) carrier in 2023 with $683 million of net earned premium and 5.8% market share; total segment net earned premiums of $756 million Specialty Property & Casualty Segment Contributes 77% of ProAssurance 2023 Net Earned Premiums • Medical Professional Liability business primarily insuring physicians and other healthcare providers and facilities • Segment includes Medical Technology Liability (life sciences), which contributed $32 million to 2023 net earned premium • Strategic initiatives over the past five years have solidified ProAssurance’s position as carrier of choice for medical professional liability coverages, leading to improved retention among smaller customers and improving accident year loss ratio.
©2024 ProAssurance • All rights reserved. 4 Remainder of ProAssurance Premiums from Workers’ Compensation Insurance and Segregated Portfolio Cell Reinsurance Segments 2023 Net Earned Premiums of $977 Million $160 Million Workers’ Compensation Insurance (Eastern Insurance) Specialty regional underwriter of workers’ compensation products and services; addressing market challenges with innovation initiatives to enhance profitability. $62 Million Segregated Portfolio Cell Reinsurance (Inova Re) Segregated Portfolio Cell Company structure offering both workers’ compensation and healthcare professional liability coverage in a Cayman- based captive, generating fee income for ProAssurance. • Corporate is ProAssurance's fourth segment • Reports investment results except those in Segregated Portfolio Cell Reinsurance segment, interest expense, U.S. and U.K. income taxes. • Includes corporate expenses and non-premium revenues generated outside of insurance entities. ProAssurance Corporate Segment
©2024 ProAssurance • All rights reserved. 5 Operational Discipline Designed for Success in Competitive Markets
©2024 ProAssurance • All rights reserved. 6 Operations – Insurance underwriting results for the third quarter of 2024, including 14% renewal pricing increases in Medical Professional Liability business, illustrate management’s ongoing actions to achieve sustained profitability • Our expertise in medical professional liability and workers’ compensation means we identified loss trends ahead of peers and have responded appropriately • Medical professional liability market challenging due to rising severity that reflects social inflation and eroding tort reform ▪ Workers' compensation market challenged by rising medical costs per claim ▪ We will not grow for growth’s sake - better to shrink to improved profitability; we are not afraid to walk away from underpriced business ▪ New and renewal business is being written at rates we believe will ultimately perform better than the business we are non-renewing Corporate – Non-GAAP adjusted book value per share was $26.52 at September 30 • There is embedded value in ProAssurance and we will consider repurchasing shares opportunistically ▪ Very strong balance sheet with high quality investment portfolio with over 90% in investment grade fixed maturities and adequate liquidity ▪ Financial leverage stable at 24% ▪ Strong net investment income growth reflects higher new purchase yields and supports return to sustained profitability ▪ Repurchased $50.5 million of common stock in 2023 with $56 million remaining in authorization Returning to Long-Term Sustained Profitability is Our Highest Priority
©2024 ProAssurance • All rights reserved. 7 Corporate Provide strong net investment income stream to bolster underwriting contribution • Leverage higher interest rate environment to increase portfolio yield • Consolidate statutory entities to maximize efficiency and capital utilization • Manage talent-acquisition and retention strategies to maximize value of work force Workers’ Compensation Insurance Minimize impact of medical inflation • Improve efficiency with newly implemented integrated policy, claims, risk management, and billing systems • Reduce loss costs by managing selection of providers and implementing cost management programs • Leverage investments in InsurTech underwriting, AI and claims data analytics to: ▪ Improve penetration in more profitable small account market segment ▪ Improve efficiency by expanding use of AI in underwriting and claims Strategic Initiatives - Addressing Challenging Markets Specialty Property & Casualty Restore profitability and support appropriate growth • Obtain rate beyond loss cost trend • Distinguish ProAssurance as carrier of choice for medical professional liability coverages ▪ Use technology to support superior customer experiences for our distribution partners and policyholders ▪ Prioritize needs of more profitable small to mid-size accounts ▪ Launch state-of-the-art workflow solution and online portal ▪ Implement straight-through processing technologies to reduce costs • Invest in innovation solutions that enhance risk selection, pricing accuracy and workflows ▪ Leverage our data science and predictive analytics capabilities to support growth in appropriate markets and sub-sectors • Assist insureds with strategies to mitigate future losses
©2024 ProAssurance • All rights reserved. 8 Specialty P&C segment combined ratio improved 8.8 percentage points primarily due to a lower net loss ratio that reflected our continued focus on price adequacy and cautious underwriting as well as our ability to target segments within healthcare where there are opportunities to write business that we believe will meet our profitability objectives. • Current accident year net loss ratio improved 0.7 percentage points over last year, primarily due to our underwriting actions and pricing we have achieved over the course of the past year. Net favorable prior accident year reserve development was $19.7 million. Medical Professional Liability claims closed favorably relative to carried reserves in the ProAssurance legacy business for accident years 2018 and prior as well as accident year 2021 from our NORCAL book. • Renewal pricing remained strong at 13% for the segment, while new business of $8.3 million remained below last year as we focus on risk selection and pricing levels that support progress toward our profitability targets. We believe we are ahead of many of our peers in achieving rate levels in medical professional liability that outpace severity trends that remain challenging. We continue to forgo renewal and new business opportunities that we believe do not meet our expectation of rate adequacy in the current loss environment, although retention was a solid 84%. Third Quarter Operating EPS of 34 Cents Comparisons to third quarter 2023 unless otherwise noted . • Specialty P&C segment combined ratio of 99.5% demonstrates progress resulting from management’s ongoing actions focused on achieving sustained profitability • Net investment income rose 14% as we take advantage of the current interest rate environment as our portfolio matures Workers’ Compensation Insurance segment combined ratio improved 10 percentage points over full-year 2023 due to a lower calendar year net loss ratio. • Current accident year net loss ratio of 77.0% improved 4.3 points from the 81.3% for full-year 2023. We also continue to observe and address the higher medical loss cost trends that we initially saw in the second half of 2023, although they have begun to moderate this year. There was no change in prior accident year reserves for this segment in this year’s third quarter compared to substantial reserve strengthening in last year’s third quarter due to the higher than expected loss trends observed at that time. • Higher audit premiums were the primary reason for the increase in net written premiums. We continue to carefully manage our underwriting appetite due to market conditions. Retention was 82% although we saw improved renewal pricing and an increase in payroll exposure. New business was $3.3 million, down from $5.4 million in last year’s third quarter.
©2024 ProAssurance • All rights reserved. 9 ProAssurance Overview
©2024 ProAssurance • All rights reserved. 10 A Foundation in Excellence SUPERIOR BRAND IDENTITY AND REPUTATION IN THE MARKET SCOPE & SCALE Regional hubs combined with local knowledge of market dynamics and regulatory environments HISTORY OF SUCCESSFUL MERGERS & ACQUISITIONS Selective M&A with best-in-class partners, and nearly 20 transactions in our 47-year history EXPERIENCED & COLLABORATIVE LEADERSHIP Average executive leadership tenure of 20 years with PRA or subsidiaries SPECIALIZATION Deep expertise and commitment to our customers throughout the insurance cycles enable us to outperform our peers over time “Our long history in our markets makes us confident that the cyclical lines of insurance where we do business will respond to our focused efforts.” -Ned Rand, President & CEO
©2024 ProAssurance • All rights reserved. 11 • Deep expertise and broad product spectrum in healthcare and related sciences • Consolidation in MPL → demand for comprehensive insurance solutions • Life Sciences → offer liability solutions to companies that develop, test, and deliver healthcare products in the U.S. and worldwide • Business mix shift since 2019 reflects continued focus on price adequacy and cautious underwriting as well as our ability to target segments within healthcare where there are opportunities to write business profitability Specialty Property & Casualty Segment $ in millions Medical Professional Liability Coverages Accounted for almost 90% of the Segment’s $835 Million of Gross Written Premiums in 2023
©2024 ProAssurance • All rights reserved. 12 2019 2020 2021 2022 2023 2024 Cumulative +65% Renewal Pricing* Change Since 2018 • Medical professional liability market facing increasingly unfavorable legal environment • ProAssurance focus on underwriting discipline has constrained growth ▪ Select competitors have been operating with capital levels that have allowed them to compete with pricing and underwriting standards that we believe are unsustainable ▪ ProAssurance has maintained retention levels in the mid-80s over the past five years, despite the competitive environment • Continue to rely on claims management expertise honed over nearly 50 years in this market ▪ We spend more on defense preparation than other carriers Annual Renewal Pricing Change 8.9% 11.9% 7.7% 7.2% 7.8% 9.6% Reflects early recognition of shift in Medical Professional Liability market cycle Annual renewal pricing changes with benefit of cumulative prior year actions 8.9% 21.9% 31.3% 40.7% 51.6% 66.1% * Renewal pricing reflects changes in our exposure base, deductibles, self-insurance retention limits and other policy terms and conditions.
©2024 ProAssurance • All rights reserved. 13 Managing Risk While Enhancing Competitive Posture • Limit growth except in appropriate markets and subsectors ▪ Consider specialty and venue severity when establishing underwriting appetite ▪ Continue strategic shift toward small to midsize accounts • Continue ongoing efforts to enhance our risk selection, pricing decisions and workflows: ▪ Bring data science, predictive analytics, workflow solutions and other tools on line ▪ Utilize data analytics to establish multi-tier risk models and improve retention of higher performing business • Focus on ease of doing business to improve competitive posture; price is not the only criteria ▪ Launch new web portal to promote full agency partner and insured self service options – Launch December 2024 ▪ Enhance new business and renewal work flows using new system functionality and automation – 2025 ▪ Undertake full revision of physician form and underwriting manuals for about 50% of business base to improve engagement and improve efficiency - 2025 and beyond $838.5 $793.7 $795.2 $765.1 $810.6 $833.5 $832.0 $805.0 $769.8 $742.3 76.3% 85.9% 94.8% 94.2% 104.2%105.3% 108.6% 86.8% 82.0% 84.0% 82.8% NEP Net Loss & LAE 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024** More than 20 Point Improvement in Net Loss and LAE Ratio for Specialty P&C* Since 2019 Reflects Benefits of Premium Increases and Strategic Initiatives * Accident Year Schedule P data including ULAE for combined ProAssurance Group excluding Workers' Compensation subsidiaries. Data excludes large account loss from 2019 and 2020. ** 2024 net loss ratio is for nine months ended September 30.
©2024 ProAssurance • All rights reserved. 14 Payroll Exposure by Market Segment Demonstrations Diversification of Workers’ Compensation Insurance Segment Business Serving over 32 Market Segments, Primarily in Rural Territories as of 12/31/2023 *Excludes alternative markets business ceded to the Segregated Portfolio Cell Reinsurance segment $ in millions • Proactive claim-closing strategies key to being recognized as a short- tail writer of workers’ compensation ▪ Between 2013 and 2022, averaged approximately 40% faster claims closure rate than industry ▪ 36 claims open from 2016 and prior, net of reinsurance ▪ Pharmacy spend as a percent of medical payments of 3.4% compared to the industry average of 7% • Value-added risk management services and claims/underwriting expertise build brand loyal
©2024 ProAssurance • All rights reserved. 15 Workers’ Compensation Insurance Segment Addressing Market Challenges With Innovation Initiatives • Implemented new integrated policy, claims, risk management and billing systems, paving the way for innovation initiatives • Expand use of data analytics to guide and support operational decisions in underwriting and claims, focusing on improving ease of doing business for agency partners and insureds • Capitalize on InsurTech investments, including AI, underwriting and claims data analytics, to enhance profitability, productivity and efficiency ▪ Adopting Clara Analytics AI Platform to lower medical costs and achieve better outcomes ▪ Implementing GuideWire for underwriting of more profitable small account business ▪ Adding Roots Automation “digital co-workers” capabilities to improve efficiency and effectiveness of underwriting and claims teams Use cases for Clara Analytics, a real-time augmented intelligence partner with workers’ comp expertise focused on providing optimal insurance claims outcomes, include: • Lower medical and indemnity costs with the best providers • Predict severity and balance adjuster caseload at first notice of loss • Gain insights and save expense by collating, searching and analyzing claim medical bills and records with treatment timelines and smart alerts • Grading defense and plaintiff attorneys on their outcomes in past similar claims
©2024 ProAssurance • All rights reserved. 16 Agency group or association establishes a cell SERVICES INCLUDE • Underwriting • Claims Administration • Risk Management • Reinsurance • Audit • Asset Management Services + Cell Rental Fees + Participation in profits/losses of selected cells Fee Income to PRA • Strategic partnerships with select independent agencies looking to manage controllable expenses • Alternative market solutions are in high demand • Value-added risk management services and claims/underwriting expertise • 2023 gross premiums written of $70 million ▪ Workers’ Compensation Insurance: $65 million ▪ Medical Professional Liability: $6 million ▪ 23 active cells Individually capitalized cells (companies) exist within the Inova Re structure. Assets and liabilities of each are segregated from others. Workers’ Comp and Medical Professional Liability businesses participate in select cells. ProAssurance Front Arrangement Through Inova Segregated Portfolio Cell Reinsurance Segment Segregated portfolio cells for medical professional liability and workers’ compensation provide captive insurance solutions that generate fee income with low capital requirements
©2024 ProAssurance • All rights reserved. 17 Details of our investment portfolio are available on our website at https://investor.proassurance.com/financial-information/ quarterly-investment-supplements More than 90% Fixed Maturity Portfolio in Investment Grade Bonds • New money yield of 5.2% in third quarter • Effective stewardship of capital ensures a position of financial strength through turbulent market cycles • Optimizing our allocations for better risk- adjusted returns. Ensures non-correlation of returns • Ongoing analysis of holdings to ensure lasting quality and profitability Total Investments of $4.35 billion (full-year 2023) Consolidated Portfolio Statistics 3Q24 3Q23 Average Income Yield 3.6% 3.1% Weighted Average Duration 3.24 3.28 Fixed Maturity Credit Quality (at year-end 2023)
©2024 ProAssurance • All rights reserved. 18 Contribution of Net Investment Result Rose 24% Year-To-Date ($ in thousands) 2024 Beginning Equity 1,111,980 Employee Stock Transactions 3,290 Earnings 36,575 OCI 79,381 Total Equity 1,231,226 Net Investment Income ($ in millions) 9/30/2024 9/30/2023 Change Fixed maturities $99,150 $83,680 $15,470 Equities 3,253 3,070 183 Short-term investments including Other 9,718 11,857 (2,139) BOLI 2,087 1,784 303 Investment fees and expenses (6,481) (5,677) (804) Net investment income $107,727 $94,714 $13,013 Equity in earnings (loss) of unconsolidated subsidiaries 16,383 5,450 10,933 Net investment result $124,110 $100,164 $23,946
©2024 ProAssurance • All rights reserved. 19 • ProAssurance maintains a balance sheet that ensures stability and security for our customers ▪ Targeted Premiums to Equity ratio is 0.75X • Our reserving philosophy enables success over the insurance cycles ▪ Net loss reserves of $3.3 billion at September 30, 2024 • $428 million total debt principal at September 30 ▪ $181 million of Contribution Certificates from NORCAL acquisition ▪ $122 million Term Loan ▪ $125 million Revolving Credit Agreement Financial and Operating Leverage Appropriate for Current Business Mix and Ratings AM Best Affirmed “A” (Excellent) Financial Strength Rating of Insurance Subsidies in June 2023 0.59 0.63 0.72 0.75 0.78 16% 24% 24% 25% 24% Premiums to Equity (excluding AOCI) Debt to Capital 2020 2021 2022 2023 At 9/30/2024
©2024 ProAssurance • All rights reserved. 20 Appendix
©2024 ProAssurance • All rights reserved. 21 ProAssurance Executive Leadership Executive Team bios available on our website at Investor.ProAssurance.com/OD Ned Rand - President & Chief Executive Officer Mr. Rand became President and CEO in 2019, after serving as COO, CFO, Executive VP, and Senior VP of Finance at ProAssurance since joining the company in 2004. Prior to joining ProAssurance, he served in a number of financial roles for insurance companies. Mr. Rand is a CPA and graduate of Davidson College (B.A., Economics) Dana Hendricks Executive Vice President & Chief Financial Officer Jeff Lisenby Executive Vice President & General Counsel Rob Francis President Medical Professional Liability Kevin Shook President, Workers’ Compensation & Segregated Portfolio Cell Reinsurance Karen Murphy President Life Sciences Insurance Noreen Dishart Executive Vice President & Chief Human Resources Officer
©2024 ProAssurance • All rights reserved. 22 ProAssurance Board of Directors Director bios available on our website at Investor.ProAssurance.com/OD Maye Head Frei Compensation Committee Chair Katisha T. Vance, MD Nominating/Corporate Governance Committee Chair Samuel A. Di Piazza, Jr Compensation Committee and Executive Committee Kedrick D. Adkins, Jr Audit Committee Chair Bruce D. Angiolillo, J.D. Independent Chair Executive Committee Chair Scott C. Syphax Nominating/Corporate Governance Committee Fabiola Cobarrubias, MD Audit Committee and Nominating/Corporate Governance Committee Edward L. Rand, Jr Executive Committee Richard J. Bielen Audit Committee Staci M. Pierce, J.D. Compensation Committee
©2024 ProAssurance • All rights reserved. 23 ProAssurance Group Brands Alternative Risk Transfer Workers’ CompensationSpecialty Property & Casualty MEDICAL PROFESSIONAL LIABILITY INSURANCE FOR ANESTHESIOLOGISTS
©2024 ProAssurance • All rights reserved. 24 Forward Looking Statements This presentation contains Forward Looking Statements and other information designed to convey our projections and expectations regarding future results. There are a number of factors which could cause our actual results to vary materially from those projected in this presentation. The principal risk factors that may cause these differences are described in various documents we file with the Securities and Exchange Commission, such as our Current Reports on Form 8-K, and our regular reports on Forms 10-Q and 10-K, particularly in “Item 1A, Risk Factors.” Please review this presentation in conjunction with a thorough reading and understanding of these risk factors. Non-GAAP Measures This presentation contains Non-GAAP measures, and we may reference Non-GAAP measures in our remarks and discussions with investors. The primary Non-GAAP measure we reference is Non-GAAP operating income (loss), a Non-GAAP financial measure that is widely used to evaluate performance within the insurance sector. In calculating Non- GAAP operating income (loss), we have excluded the after-tax effects of net realized investment gains or losses, foreign currency exchange gains or losses and guaranty fund assessments or recoupments that do not reflect normal operating results. We believe Non-GAAP operating income presents a useful view of the performance of our insurance operations, but should be considered in conjunction with net income (loss) computed in accordance with GAAP. A reconciliation of these measures to GAAP measures is available in our regular reports on Forms 10-Q and 10-K and in our latest quarterly news release, all of which are available in the Investor Relations section of our website, Investor.ProAssurance.com. Important Safe Harbor and Non-GAAP Notices
25 Contact: Heather J. Wietzel SVP, Investor Relations 205-776-3028 InvestorRelations@ProAssurance.com Mailing Address: ProAssurance Corporation 100 Brookwood Place Birmingham, AL 35209
v3.24.3
Document and Entity Information Document
|
Nov. 07, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Entity Registrant Name |
ProAssurance Corporation
|
Entity Incorporation, State or Country Code |
DE
|
Entity File Number |
001-16533
|
Entity Tax Identification Number |
63-1261433
|
Entity Central Index Key |
0001127703
|
Amendment Flag |
false
|
Entity Address, Address Line One |
100 Brookwood Place,
|
Entity Address, City or Town |
Birmingham,
|
Entity Address, State or Province |
AL
|
Entity Address, Postal Zip Code |
35209
|
City Area Code |
(205)
|
Local Phone Number |
877-4400
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.01 per share
|
Trading Symbol |
PRA
|
Security Exchange Name |
NYSE
|
Entity Emerging Growth Company |
false
|
Document Period End Date |
Nov. 07, 2024
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
ProAssurance (NYSE:PRA)
Historical Stock Chart
From Oct 2024 to Nov 2024
ProAssurance (NYSE:PRA)
Historical Stock Chart
From Nov 2023 to Nov 2024